Cargando…

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens. We describe here patients’ profiles and management in daily practice in France. METHODS: Observational retrospective study. Data w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raynaud, C., Greillier, L., Mazieres, J., Monnet, I., Mastroianni, B., Robinet, G., Fraboulet, G., Dixmier, A., Berard, H., Lamy, R., Letreut, J., Lena, H., Oliviero, G., Botta, S., Vergnenegre, A., Borget, I., Chouaid, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635998/ https://www.ncbi.nlm.nih.gov/pubmed/26546402 http://dx.doi.org/10.1186/s12885-015-1881-x

Ejemplares similares

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
por: Vergnenègre, A, et al.
Publicado: (2013)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
por: Arpin, Dominique, et al.
Publicado: (2020)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
por: Chouaïd, Christos, et al.
Publicado: (2014)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
por: Lesueur, Paul, et al.
Publicado: (2018)

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
por: LeCaer, H, et al.
Publicado: (2011)

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
por: Chouaid, Christos, et al.
Publicado: (2018)

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2022)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

The role of KIR2DL3/HLA-C*0802 in Brazilian patients with rheumatoid vasculitis
por: Nishimura, Wester Eidi, et al.
Publicado: (2015)

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
por: Boyer, Arnaud, et al.
Publicado: (2018)

Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)
por: Sun, Yongkun, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
por: Assié, Jean-Baptiste, et al.
Publicado: (2022)

Effect on eNOS/NO Pathway in MIRI rats with preconditioning of GFPC from Dang Gui Si Ni decoction
por: Qian, Guo-qiang, et al.
Publicado: (2014)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Controversies in the role of radiotherapy in pleural mesothelioma
por: Hanna, Gerard G., et al.
Publicado: (2021)

Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
por: Dick, I.M., et al.
Publicado: (2022)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

OA08.02. Differential acute effects of real and sham acupuncture on mu-opioid receptor availability in treatment naive and conditioned chronic pain patients
por: Akbar, N, et al.
Publicado: (2012)

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
por: Ceresoli, G L, et al.
Publicado: (2014)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma
por: Zauderer, Marjorie G.
Publicado: (2021)

Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
por: Gray, Steven G.
Publicado: (2021)

Is the ratio of pleural mesothelioma mortality to pleural cancer mortality approximately unity for Italy? Considerations from the oldest regional mesothelioma register in Italy
por: Gorini, G, et al.
Publicado: (2002)

In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma
por: Rouka, Erasmia, et al.
Publicado: (2019)

Different Algicidal Modes of the Two Bacteria Aeromonas bestiarum HYD0802-MK36 and Pseudomonas syringae KACC10292(T) against Harmful Cyanobacteria Microcystis aeruginosa
por: Park, Bum Soo, et al.
Publicado: (2022)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
por: Vergnenègre, Alain, et al.
Publicado: (2012)

Localized malignant pleural mesothelioma with renal metastasis
por: Zardawi, Sarah Jane, et al.
Publicado: (2015)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_nbefucrj0emc3l00p8rv9iqstp